Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigamox for Ocular Graft-Versus-Host Disease
NCT04204122Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial in ocular graft-versus-host disease (oGVHD) comparing Vigamox Eye with Placebo Eye (2 arms). Primary endpoint: Change in Ocular comfort at 2 weeks. Planned start Jun 2020; status: withdrawn.
02
Drugs
moxifloxacin
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT04204122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204122.